<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959517</url>
  </required_header>
  <id_info>
    <org_study_id>T26/181/33 A00017</org_study_id>
    <secondary_id>TDR A00017</secondary_id>
    <nct_id>NCT00959517</nct_id>
  </id_info>
  <brief_title>Trial of Artesunate Combination Therapy in Pakistan</brief_title>
  <official_title>Pseudo-randomised, Double-blinded Placebo-controlled Trial of Chloroquine or Sulphadoxine-pyrimethamine Alone or in Combination With Primaquine or Artesunate for the Treatment of Uncomplicated Falciparum Malaria in Pakistan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HealthNet TPO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an evaluation of the benefit of adding artesunate to existing first and second&#xD;
      line antimalarial therapies in Pakistan.&#xD;
&#xD;
      A placebo controlled trial was carried out to assess two potential benefits of Artesunate&#xD;
      Combination Therapy (ACT): efficacy and potential for transmission reduction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised, double-blind placebo controlled study of the efficacy of chloroquine or&#xD;
      sulphadoxine-pyrimethamine alone and in combination with primaquine or artesunate for the&#xD;
      treatment of uncomplicated falciparum malaria.&#xD;
&#xD;
      Arms:&#xD;
&#xD;
        1. CQ&#xD;
&#xD;
        2. CQ+primaquine&#xD;
&#xD;
        3. CQ+ artesunate&#xD;
&#xD;
        4. SP&#xD;
&#xD;
        5. SP+primaquine&#xD;
&#xD;
        6. SP+artesunate&#xD;
&#xD;
      Patients were allocated to treatment groups using a pseudo-randomised table split by age and&#xD;
      sex.&#xD;
&#xD;
      Primary outcomes:&#xD;
&#xD;
        -  Clinical and parasitological cure/treatment failure by day 28.&#xD;
&#xD;
      Secondary outcomes:&#xD;
&#xD;
        -  time to resolution of fever&#xD;
&#xD;
        -  time to clearance of trophozoites&#xD;
&#xD;
        -  time to clearance of gametocytes&#xD;
&#xD;
        -  gametocyte carriage on or after day 7 after treatment&#xD;
&#xD;
      All clinical assessments and slide readings were carried out by staff blind to treatment arm.&#xD;
      Slides were double read.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parasitological outcome after 28 days follow-up</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asexual parasite clearance by day 7</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gametocyte carriage on or after day 7</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">588</enrollment>
  <condition>Uncomplicated Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>CQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CQ+PQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CQ + AS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SP + PQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SP + AS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>artesunate (AS)</intervention_name>
    <description>Recommended dosage over 3 days (for all interventions)</description>
    <arm_group_label>CQ + AS</arm_group_label>
    <arm_group_label>SP + AS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulphadoxine-pyrimethamine (SP)</intervention_name>
    <arm_group_label>SP</arm_group_label>
    <arm_group_label>SP + AS</arm_group_label>
    <arm_group_label>SP + PQ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine (CQ)</intervention_name>
    <arm_group_label>CQ</arm_group_label>
    <arm_group_label>CQ + AS</arm_group_label>
    <arm_group_label>CQ+PQ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>primaquine (PQ)</intervention_name>
    <arm_group_label>CQ+PQ</arm_group_label>
    <arm_group_label>SP + PQ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  presentation at basic health unit with suspected clinical malaria&#xD;
&#xD;
          -  mono-infection infection with P. falciparum confirmed by microscopy&#xD;
&#xD;
          -  over 2 years of age (no upper age restriction)&#xD;
&#xD;
          -  weight over 5 kg (no upper weight restriction)&#xD;
&#xD;
          -  if of child bearing age then non-pregnant and willing to remain so for the duration of&#xD;
             the study&#xD;
&#xD;
          -  greater than 1 asexual parasite per 10 fields&#xD;
&#xD;
          -  understands and is willing to sign the consent form&#xD;
&#xD;
          -  a resident in the study site willing to collaborate for a full period of follow-up&#xD;
&#xD;
          -  no signs of severe malaria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other serious disease (e.g., cardiac, renal or hepatic)&#xD;
&#xD;
          -  in women of child bearing age, pregnancy&#xD;
&#xD;
          -  allergy to any of the study drugs or related compounds&#xD;
&#xD;
          -  reports to have used any malaria drugs in the last 21 days&#xD;
&#xD;
          -  other species of malaria seen&#xD;
&#xD;
          -  signs of severe malaria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark W Rowland, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HealthNet International</name>
      <address>
        <city>Peshawar</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>August 13, 2009</study_first_submitted>
  <study_first_submitted_qc>August 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2009</study_first_posted>
  <last_update_submitted>August 13, 2009</last_update_submitted>
  <last_update_submitted_qc>August 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr Mark Rowland</name_title>
    <organization>London School of Hygiene &amp; Tropical Medicine</organization>
  </responsible_party>
  <keyword>Placebo controlled</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Artemisinin-based combination therapy</keyword>
  <keyword>Primaquine</keyword>
  <keyword>Gametocytes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Primaquine</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

